Search

Objetivo: establecer la prevalencia de vida de orgasmo femenino y de dificultades orgásmicas en universitarias del área metropolitana de Bucara manga (Colombia). Materiales y métodos: estudio de corte transversal. Se administró un cuestionario de autorreporte a una muestra de mujeres universitarias de Bucaramanga. Además de la prevalencia de orgasmo, se midieron variables sociodemográficas como edad, orientación sexual, religiosidad y estado civil; y variables relacionadas con la conducta y la estimulación sexual. Se realizó un análisis descriptivo y un análisis exploratorio mediante análisis bivariado y multivariado para medir la asociación de variables de interés con el orgasmo. Resultados: se encuestaron 1.038 mujeres, con una edad mediana de 20 años. La prevalencia de vida de orgasmo fue del 76 % (IC 95 %: 73,5-78,7) y la prevalencia de dificultades para alcanzar el orgasmo fue del 24 % (IC 95 %: 21,3-26,5). De las mujeres que no habían tenido orgasmo o tenían dificultades para alcanzarlo el 6,2 % habían consultado al ginecólogo por esta razón. En el análisis multivariado se encontró asociación entre el orgasmo y la edad (OR = 1,19; IC 95%: 1,08-1,31), la masturbación (OR = 2,55; IC 95 %: 1,34-4,84) y las relaciones sexuales con una pareja (OR = 4,2; IC 95 %: 2,28-7,72). Conclusión: una de cada 3 mujeres universitarias no han tenido experiencia orgásmica y tres de cada 10 mujeres con experiencia orgásmica reportan dificultad para alcanzarlo. Es importante indagar sobre estos problemas sexuales en la consulta de ginecología.

Abstract Background Chronic limb-threatening ischemia (CLTI) represents the final stage of peripheral arterial disease. Approximately one-third of patients with CLTI are not eligible for conventional surgical treatments. Furthermore, patients with advanced stage of CLTI are prone to amputation and death. Thus, an effective therapeutic strategy is urgently needed. In this context, autologous bone marrow mononuclear cell (auto-BM-MNC) and allogeneic mesenchymal stem cells represent a promising therapeutic approach for treating CLTI. In this study, we compared the safety and beneficial therapeutic effect of auto-BM-MNC versus allogeneic Wharton jelly-derived mesenchymal stem cells (allo-WJ-MSCs) in diabetic patients with CLTI. Methods We performed a randomized, prospective, double-blind and controlled pilot study. Twenty-four diabetic patients in the advanced stage of CLTI (4 or 5 in Rutherford’s classification) and a transcutaneous oxygen pressure (TcPO2) below 30 mmHg were randomized to receive 15 injections of (i) auto-BM-MNC (7.197 × 106 ± 2.984 × 106 cells/mL) (n = 7), (ii) allo-WJ-MSCs (1.333 × 106 cells/mL) (n = 7) or (iii) placebo solution (1 mL) (n = 10), which were administered into the periadventitial layer of the arterial walls under eco-Doppler guidance. The follow-up visits were at months 1, 3, 6, and 12 to evaluate the following parameters: (i) Rutherford’s classification, (ii) TcPO2, (iii) percentage of wound closure, (iv) pain, (v) pain-free walking distance, (vi) revascularization and limb-survival proportion, and (vii) life quality (EQ-5D questionnaire). Results No adverse events were reported. Patients with CLTI who received auto-BM-MNC and allo-WJ-MSCs presented an improvement in Rutherford’s classification, a significant increase in TcPO2 values‬, a reduction in the lesion size in a shorter time, a decrease in the pain score and an increase in the pain-free walking distance, in comparison with the placebo group. In addition, the participants treated with auto-BM-MNC and allo-WJ-MSCs kept their limbs during the follow-up period, unlike the placebo group, which had a marked increase in amputation. Conclusions Our results showed that patients with CLTI treated with auto-BM-MNC and allo-WJ-MSCs conserved 100% of their limb during 12 months of the follow-up compared to the placebo group, where 60% of participants underwent limb amputation in different times. Furthermore, we observed a faster improvement in the allo-WJ-MSC group, unlike the auto-BM-MNC group. Trial registration This study was retrospectively registered at ClinicalTrials.gov (NCT05631444).